Dr. Ku on Immunotherapy in Gastric and Esophageal Cancer | OncLive

Dr. Ku on Immunotherapy in Gastric and Esophageal Cancer

February 9, 2017

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.

Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.

Researchers of a phase III study tested almost 500 patients who had previously received 2 or more chemotherapy treatments. These patients were treated with either nivolumab (Opdivo), the PD-1 antibody, or placebo.

There was a 12-month overall survival rate of 27% in these patients versus the 11% in patients who had received placebo. For the first time, this phase III evidence confirmed that these drugs are active in patients with gastric and esophageal cancers, says Ku.


x